Rheumatoid arthritis drug combined with standard of care may help reduce mortality for hospitalized COVID-19 patients
Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine.
By Nancy Humphrey